Results 261 to 270 of about 35,799 (284)
Some of the next articles are maybe not open access.
Drugs of Today, 2007
Dasatinib is an orally bioavailable potent inhibitor of multiple tyrosine kinases, including ABL and SRC. Preclinical studies have shown dasatinib to be a much more potent inhibitor of BCR-ABL than imatinib is, and to harbor efficacy against nearly all imatinib-resistant BCR-ABL mutants.
openaire +2 more sources
Dasatinib is an orally bioavailable potent inhibitor of multiple tyrosine kinases, including ABL and SRC. Preclinical studies have shown dasatinib to be a much more potent inhibitor of BCR-ABL than imatinib is, and to harbor efficacy against nearly all imatinib-resistant BCR-ABL mutants.
openaire +2 more sources
Hospital Pharmacy, 2007
The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant
Waddell, Dominic A. Solimando, Bussey
openaire +2 more sources
The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant
Waddell, Dominic A. Solimando, Bussey
openaire +2 more sources
Dasatinib, an immunomodulator?
Blood, 2010In this issue of Blood, Kreutzman and colleagues describe the existence of clonal cytotoxic T and NK cells in over 80% (15 of 18) of patients with CML at diagnosis which persisted during treatment with the tyrosine kinase inhibitors, imatinib and dasatinib.1 Furthermore, they discovered that this clonal lymphocytosis expands further after therapy with ...
openaire +3 more sources
Solvates of Dasatinib: Diversity and Isostructurality
Journal of Pharmaceutical Sciences, 2016A series of dasatinib crystalline forms were obtained, and a hierarchical cluster analysis of their powder X-ray diffraction patterns was performed. The resulting dendrogram implies 3 structural groups. The crystal structures of several solvates representing 2 of these groups were determined. The crystal structure analysis confirms the isostructurality
Sarceviča, I. +6 more
openaire +4 more sources
Pleural effusions due to dasatinib
Current Opinion in Pulmonary Medicine, 2010Dasatinib is a novel tyrosine-kinase inhibitor approved for treatment of BCR-ABL positive chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) after imatinib failure. Use of dasatinib is frequently complicated by pleural effusions.
Anupama G. Brixey, Richard W. Light
openaire +3 more sources
Dasatinib-Induced Transverse Melanonychia
Skin Appendage Disorders, 2023Introduction: Transverse melanonychia, characterized by grey to black pigmented bands traversing the nail plate, can occur as a side-effect of certain medications. While no documented reports specifically associate dasatinib, a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia, with ...
Mehul, Tyagi +2 more
openaire +2 more sources
2017
Dasatinib (Sprycel, BMS) is a short-acting multikinase inhibitor that mostly interferes with Abelson murine leukemia (ABL), breakpoint cluster region (BCR)-ABL, and SRC kinase family members (SRC, LCK, YES, FYN). Additionally, dasatinib inhibits the TEC family (TEC, BTK), and some receptor tyrosine kinases, such as KIT, PDGFRβ, DDR1, DDR2, FMS, and ...
openaire +2 more sources
Dasatinib (Sprycel, BMS) is a short-acting multikinase inhibitor that mostly interferes with Abelson murine leukemia (ABL), breakpoint cluster region (BCR)-ABL, and SRC kinase family members (SRC, LCK, YES, FYN). Additionally, dasatinib inhibits the TEC family (TEC, BTK), and some receptor tyrosine kinases, such as KIT, PDGFRβ, DDR1, DDR2, FMS, and ...
openaire +2 more sources
Pharmacokinetic interactions of dasatinib and docetaxel
The Lancet Oncology, 20141reported that the addition of dasatinib to docetaxel neither improved survival in patients with advanced prostate cancer, nor increased the haematological toxic eff ects of the taxane. They did not discuss whether some of these results might have arisen from the potential pharmacokinetic interaction between the two drugs.
openaire +3 more sources
Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies
Medical Oncology, 2023Fauziya +9 more
semanticscholar +1 more source
Dasatinib-Induced Platelet Dysfunction.
Blood, 2007Abstract Dasatinib is efficacious and safe in patients (pts) with chronic myelogenous leukemia (CML) after imatinib failure. However, dasatinib therapy has been linked to bleeding in some pts, typically affecting mucosal surfaces. We analyzed the effect of dasatinib on basic coagulation tests and platelet aggregation function in 55 pts ...
Alfonso Quintás-Cardama +3 more
openaire +2 more sources